Cordis will highlight insights from the SELUTION SLR™ Drug-Eluting Balloon clinical trial program at Cardiovascular Research ...
SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% primary ...
MIAMI LAKES, Fla., Oct. 24, 2023 /PRNewswire/ -- Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, has announced completion ...
Mumbai (Maharashtra) [India], November 11: Cordis, a global leader in interventional cardiovascular technology, announced the groundbreaking results from the SELUTION DeNovo and SELUTION4ISR trials at ...
GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent ...
GENEVA, June 7, 2022 /PRNewswire/ -- The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting ...
Cordis Corp. covered its bets a bit as it closed the acquisition of M.A. Med Alliance SA (Medalliance) announced almost a year ago. While the total payment for the company could total $1.135 billion, ...
GENEVA, Jan. 10, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results